From 2025 to 2035, residual current circuit breaker market is expected to flourish at a CAGR of 6.7%. By 2035, the market ...

Kuro Games announced the events and banners for Wuthering Waves version 2.3 Phase 2 (Image via Kuro Games) Kuro Games announced all the events and banners coming with Wuthering Waves 2.3 second phase.

Dive into Sprunki MSI Canon Phase 3, where new characters and immersive soundscapes deepen the narrative. Experience a thrilling evolution of dark themes. Sprunki MSI Phase 3 represents a thrilling ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled nerandomilast “a step forward but not game-changing.” Boehringer revealed ...

The Massachusetts biotech reported May 19 that AD109 met the primary endpoint of a phase 3 trial, reducing sleep apnea severity by a statistically significant 55.6% compared to baseline.

"He was here (at Halas Hall) early. He spends extra time with coach. "I think Year 3 is such a critical time where you could take that big leap. You play some football, you can get more ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

The surge in the stock price came after the company ... to manufacture fans (in phase-1) and other categories later. “We maintain FY26/27 earnings per share (EPS) estimates and believe these ...

AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically ...

The preliminary trial results announced Monday are from a Phase 3 test that enrolled 646 adults in the U.S. and Canada who have mild, moderate, or severe OSA and either cannot tolerate CPAP ...

But with promising early results from a phase 3 study in certain patients, the checkpoint inhibitor may have found its place. At a pre-specified interim analysis of Merck’s phase 3 Keynote-B96 ...